Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935617 | 1.00 | FAAH (0.40) | FAAHTRPV1FFAR1FFAR4SOAT2 | |
| SCHEMBL2637018 | 1.00 | FAAH (0.40) | FAAHTRPV1FFAR1FFAR4SOAT2 | |
| SCHEMBL2637017 | 1.00 | FAAH (0.40) | FAAHTRPV1FFAR1FFAR4SOAT2 | |
| SCHEMBL2636981 | 0.94 | FFAR1 (0.36) | FAAHTRPV1FFAR1FFAR4SOAT2 | |
| SCHEMBL2636982 | 0.94 | FFAR1 (0.36) | FAAHTRPV1FFAR1FFAR4SOAT2 | |
| SCHEMBL16705754 | 0.91 | TSHR (0.39) | FAAHTRPV1TSHRCYP1A2CYP3A4 | |
| SCHEMBL2641777 | 0.89 | ALDH1A1 (0.41) | TRPV1FFAR1FFAR4SOAT2SOAT1 | |
| SCHEMBL2641780 | 0.89 | ALDH1A1 (0.41) | TRPV1FFAR1FFAR4SOAT2SOAT1 | |
| SCHEMBL14935363 | 0.89 | ALDH1A1 (0.41) | TRPV1FFAR1FFAR4SOAT2SOAT1 | |
| SCHEMBL2641862 | 0.89 | ALDH1A1 (0.41) | TRPV1FFAR1FFAR4SOAT2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569276-B1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2021-02-24 | — | — | EP | disclosed |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-09-10 | — | — | US | disclosed |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-06-01 | — | — | US | disclosed |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-06-01 | — | — | US | disclosed |
| US-8865675-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-10-21 | — | — | US | disclosed |
| US-8865675-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-10-21 | — | — | US | disclosed |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | FAAH 3580/4885TRPV1 3680/4885FFAR1 933/4885 |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | FAAH 3580/4885TRPV1 3680/4885FFAR1 933/4885 |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | FAAH 2495/4885TRPV1 4749/4885FFAR1 1527/4885 |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | FAAH 3580/4885TRPV1 3680/4885FFAR1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.